USA - NASDAQ:ARTV - US04317A1079 - Common Stock
ChartMill assigns a Buy % Consensus number of 85% to ARTV. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-17 | Needham | Reiterate | Buy -> Buy |
| 2025-10-17 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-05-15 | Needham | Maintains | Buy -> Buy |
| 2025-04-08 | Needham | Reiterate | Buy -> Buy |
| 2025-03-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-25 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-03-25 | Needham | Reiterate | Buy -> Buy |
| 2025-03-25 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-12-30 | HC Wainwright & Co. | Initiate | Buy |
| 2024-11-13 | Needham | Reiterate | Buy -> Buy |
| 2024-08-30 | Needham | Reiterate | Buy -> Buy |
| 2024-08-13 | TD Cowen | Initiate | Buy |
| 2024-08-13 | Cantor Fitzgerald | Initiate | Overweight |
| 2024-08-13 | Needham | Initiate | Buy |
| 2024-08-13 | Wedbush | Initiate | Outperform |
| 2024-08-13 | Jefferies | Initiate | Buy |
12 analysts have analysed ARTV and the average price target is 16.73 USD. This implies a price increase of 383.47% is expected in the next year compared to the current price of 3.46.
The consensus rating for ARTIVA BIOTHERAPEUTICS INC (ARTV) is 85 / 100 . This indicates that analysts generally have a positive outlook on the stock.